|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MIR99AHG |
Gene summary for MIR99AHG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MIR99AHG | Gene ID | 388815 |
| Gene name | mir-99a-let-7c cluster host gene | |
| Gene Alias | C21orf34 | |
| Cytomap | 21q21.1 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 388815 | MIR99AHG | CCI_1 | Human | Cervix | CC | 4.30e-25 | 9.69e-01 | 0.528 |
| 388815 | MIR99AHG | CCI_2 | Human | Cervix | CC | 2.30e-10 | 4.53e-01 | 0.5249 |
| 388815 | MIR99AHG | CCI_3 | Human | Cervix | CC | 2.23e-38 | 1.49e+00 | 0.516 |
| 388815 | MIR99AHG | sample1 | Human | Cervix | CC | 2.17e-17 | 4.67e-01 | 0.0959 |
| 388815 | MIR99AHG | H2 | Human | Cervix | HSIL_HPV | 4.00e-05 | 1.43e-01 | 0.0632 |
| 388815 | MIR99AHG | T1 | Human | Cervix | CC | 2.90e-30 | 5.80e-01 | 0.0918 |
| 388815 | MIR99AHG | AEH-subject2 | Human | Endometrium | AEH | 1.10e-02 | 1.63e-02 | -0.2525 |
| 388815 | MIR99AHG | EEC-subject3 | Human | Endometrium | EEC | 1.19e-04 | -5.19e-02 | -0.2525 |
| 388815 | MIR99AHG | GSM5276935 | Human | Endometrium | EEC | 4.83e-03 | -1.25e-01 | -0.123 |
| 388815 | MIR99AHG | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.20e-05 | -1.53e-01 | -0.1869 |
| 388815 | MIR99AHG | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.64e-04 | -1.53e-01 | -0.1875 |
| 388815 | MIR99AHG | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.15e-05 | -1.53e-01 | -0.1883 |
| 388815 | MIR99AHG | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.89e-07 | -1.53e-01 | -0.1934 |
| 388815 | MIR99AHG | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.89e-07 | -1.53e-01 | -0.1917 |
| 388815 | MIR99AHG | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 4.40e-08 | -1.53e-01 | -0.1916 |
| 388815 | MIR99AHG | LZE3D | Human | Esophagus | HGIN | 7.42e-03 | 3.84e-01 | 0.0668 |
| 388815 | MIR99AHG | P2T-E | Human | Esophagus | ESCC | 1.12e-09 | -7.48e-02 | 0.1177 |
| 388815 | MIR99AHG | P4T-E | Human | Esophagus | ESCC | 2.73e-16 | 5.41e-01 | 0.1323 |
| 388815 | MIR99AHG | P5T-E | Human | Esophagus | ESCC | 2.63e-03 | -1.24e-01 | 0.1327 |
| 388815 | MIR99AHG | P8T-E | Human | Esophagus | ESCC | 6.19e-05 | 6.06e-03 | 0.0889 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |